GILEAD SCIENCES, INC. Increase (Decrease) in Deferred Revenue
GILEAD SCIENCES, INC. (GILD) reported Increase (Decrease) in Deferred Revenue of -$304.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2017-02-27
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-12-31 was -$156.00M, a 620.00% decline year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-09-30 was $14.00M.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-06-30 was -$199.00M, a 165.46% decline year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2016-03-31 was $37.00M, a 39.34% decline year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2016 was -$304.00M, a 181.28% decline from fiscal 2015.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2015 was $374.00M, a 1106.45% increase from fiscal 2014.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2014 was $31.00M, a 40.91% increase from fiscal 2013.
- GILEAD SCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2013 was $22.00M, a 4.35% decline from fiscal 2012.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 6 month as first filed | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | -$156.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$142.00M derived: sum of 2 quarters · filed 2017-02-27 | -$341.00M derived: sum of 3 quarters · filed 2017-02-27 | -$304.00M 10-K · filed 2017-02-27 | ||||
| 2016-09-30 | $14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$185.00M derived: sum of 2 quarters · filed 2016-11-07 | -$148.00M 10-Q · filed 2016-11-07 | -$118.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2016-06-30 | -$199.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$162.00M 10-Q · filed 2016-08-05 | -$132.00M derived: sum of 3 quarters · filed 2017-02-27 | -$153.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2016-03-31 | $37.00M 10-Q · filed 2016-05-06 | $67.00M derived: sum of 2 quarters · filed 2017-02-27 | $46.00M derived: sum of 3 quarters · filed 2017-02-27 | $350.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $9.00M derived: sum of 2 quarters · filed 2017-02-27 | $313.00M derived: sum of 3 quarters · filed 2017-02-27 | $374.00M 10-K · filed 2017-02-27 | ||||
| 2015-09-30 | -$21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $283.00M derived: sum of 2 quarters · filed 2016-11-07 | $344.00M 10-Q · filed 2016-11-07 | $363.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $304.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $365.00M 10-Q · filed 2016-08-05 | $384.00M derived: sum of 3 quarters · filed 2017-02-27 | $376.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $61.00M 10-Q · filed 2016-05-06 | $80.00M derived: sum of 2 quarters · filed 2017-02-27 | $72.00M derived: sum of 3 quarters · filed 2017-02-27 | $89.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $11.00M derived: sum of 2 quarters · filed 2017-02-27 | $28.00M derived: sum of 3 quarters · filed 2017-02-27 | $31.00M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | -$8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $9.00M derived: sum of 2 quarters · filed 2015-11-04 | $12.00M 10-Q · filed 2015-11-04 | $12.31M 10-Q · filed 2014-11-05 | $4.94M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $20.00M 10-Q · filed 2015-08-05 | $19.83M 10-Q · filed 2014-08-04 | $12.94M derived: sum of 3 quarters · filed 2016-02-24 | $24.81M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-03-31 | $3.00M 10-Q · filed 2015-05-08 | $3.27M 10-Q · filed 2014-05-07 | -$4.06M derived: sum of 2 quarters · filed 2016-02-24 | $7.81M derived: sum of 3 quarters · filed 2016-02-24 | -$7.88M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | -$7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $4.81M derived: sum of 2 quarters · filed 2016-02-24 | -$10.88M derived: sum of 3 quarters · filed 2016-02-24 | $22.00M 10-K · filed 2016-02-24 | $22.14M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $11.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$3.82M derived: sum of 2 quarters · filed 2014-11-05 | $29.06M 10-Q · filed 2014-11-05 | $44.82M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | -$15.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $17.19M 10-Q · filed 2014-08-04 | $32.95M derived: sum of 3 quarters · filed 2015-02-25 | $29.39M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $32.88M 10-Q · filed 2014-05-07 | $48.64M derived: sum of 2 quarters · filed 2015-02-25 | $45.09M derived: sum of 3 quarters · filed 2015-02-25 | $35.70M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $12.21M derived: sum of 2 quarters · filed 2015-02-25 | $2.82M derived: sum of 3 quarters · filed 2015-02-25 | $23.00M 10-K · filed 2015-02-25 | $23.25M 10-K · filed 2013-02-27 | |||
| 2012-09-30 | -$3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | -$12.94M derived: sum of 2 quarters · filed 2013-10-31 | $7.24M 10-Q · filed 2013-10-31 | $10.40M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | -$9.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $10.79M 10-Q · filed 2013-08-01 | $13.95M derived: sum of 3 quarters · filed 2014-02-25 | $26.38M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $20.18M 10-Q · filed 2013-05-08 | $23.33M derived: sum of 2 quarters · filed 2014-02-25 | $35.76M derived: sum of 3 quarters · filed 2014-02-25 | -$937.00K derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $3.16M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $15.59M derived: sum of 2 quarters · filed 2014-02-25 | -$21.11M derived: sum of 3 quarters · filed 2014-02-25 | -$29.48M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $12.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$24.27M derived: sum of 2 quarters · filed 2012-11-06 | -$32.64M 10-Q · filed 2012-11-06 | -$31.86M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-06-30 | -$36.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$45.07M 10-Q · filed 2012-08-01 | -$44.29M derived: sum of 3 quarters · filed 2013-02-27 | -$64.94M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-03-31 | -$8.37M 10-Q · filed 2012-05-04 | -$7.59M derived: sum of 2 quarters · filed 2013-02-27 | -$28.24M derived: sum of 3 quarters · filed 2013-02-27 | -$36.08M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2010-12-31 | $779.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$19.87M derived: sum of 2 quarters · filed 2013-02-27 | -$27.71M derived: sum of 3 quarters · filed 2013-02-27 | -$29.73M 10-K · filed 2013-02-27 | ||||
| 2010-09-30 | -$20.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$28.49M derived: sum of 2 quarters · filed 2011-11-04 | -$30.51M 10-Q · filed 2011-11-04 | $41.31M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-06-30 | -$7.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | -$9.86M 10-Q · filed 2011-08-05 | $61.96M derived: sum of 3 quarters · filed 2012-02-23 | $56.12M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2010-03-31 | -$2.02M 10-Q · filed 2011-05-09 | $69.80M derived: sum of 2 quarters · filed 2012-02-23 | $63.97M derived: sum of 3 quarters · filed 2012-02-23 | $64.14M derived: sum of 4 quarters · filed 2012-02-23 | ||||
| 2009-12-31 | $71.82M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $65.98M derived: sum of 2 quarters · filed 2012-02-23 | $66.16M derived: sum of 3 quarters · filed 2012-02-23 | $48.60M 10-K · filed 2012-02-23 | ||||
| 2009-09-30 | -$5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | -$5.66M derived: sum of 2 quarters · filed 2010-11-08 | -$23.21M 10-Q · filed 2010-11-08 | -$2.43M derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-06-30 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | -$17.38M 10-Q · filed 2010-08-09 | $3.40M derived: sum of 3 quarters · filed 2011-02-28 | $2.77M derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-03-31 | -$17.56M 10-Q · filed 2010-05-10 | $3.23M derived: sum of 2 quarters · filed 2011-02-28 | $2.60M derived: sum of 3 quarters · filed 2011-02-28 | |||||
| 2008-12-31 | $20.79M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $20.16M derived: sum of 2 quarters · filed 2011-02-28 | $25.08M 10-K · filed 2011-02-28 | |||||
| 2008-09-30 | -$630.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $4.29M 10-Q · filed 2009-11-05 | ||||||
| 2008-06-30 | $4.92M 10-Q · filed 2009-08-05 | |||||||
| 2007-12-31 | $13.24M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |